Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers
NCT00255359
·
clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Chronic Hepatitis C Virus Infection
Interventions
DRUG:
XTL-2125
Sponsor
Hadassah Medical Organization
Collaborators
[object Object]